Clinical Trials Logo

Androgenetic Alopecia clinical trials

View clinical trials related to Androgenetic Alopecia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06393452 Recruiting - Clinical trials for Androgenetic Alopecia

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

Start date: June 5, 2024
Phase: Phase 2
Study type: Interventional

The study is designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK following 28 days of administration.

NCT ID: NCT06239207 Recruiting - Clinical trials for Androgenetic Alopecia

Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia

Start date: September 21, 2023
Phase: Phase 2
Study type: Interventional

Androgenetic alopecia is a common condition affects both genders. Patients of androgenetic alopecia following inclusion criteria will be enrolled after ethical approval and informed consent. Pre-treatment assessment will be done by Physian Global assessment, Patient global assessment and hair density by trichoscopy of areas under treatment. Patients will be categorized in 2 groups. Group A receiving exosomes 1session intradermally in scalp after nerve block and group B receiving PRP 2 sessions of PRP 1 month apart intradermally in scalp after nerve block. Patients will receive exosomes at strength of 2 to 10 billion particles/5ml with 0.1 ml/cm2. Follow up will be done after 1 month, 2 months, 3 months, 5 months and 6 months of completion of treatment to assess hair growth and reduce hair fall by Physian Global assessment (PGA), Patient global assessment (PtGA) and trichography. Clinical response will be graded as satisfactory (< 25%), good (25-50%) or excellent (> 50%) improvement. Details will be entered on predesigned proforma. Data will be entered and analyzed using SPSS 27. Means will be calculated for quantitative variables, frequencies for qualitative variables like pre- and post treatment response. Data will be stratified for role of effect modifiers

NCT ID: NCT06218498 Recruiting - Clinical trials for Androgenetic Alopecia

Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Er Laser for the Treatment of Androgenetic Alopecia

Start date: November 24, 2023
Phase: N/A
Study type: Interventional

Laser sources have established their potential effect in inducing hair regrowth. No study has compared the effect of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (AGA).

NCT ID: NCT06218394 Recruiting - Clinical trials for Androgenetic Alopecia

Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia

Start date: December 14, 2023
Phase: N/A
Study type: Interventional

Microneedling and autologous concentrated growth factor (CGF) have established their potential effect in inducing hair regrowth. No study has compared the effect of microneedling and CGF in the treatment of female androgenetic alopecia (AGA).

NCT ID: NCT06118866 Recruiting - Clinical trials for Androgenetic Alopecia

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Start date: September 11, 2023
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks

NCT ID: NCT05990400 Recruiting - Clinical trials for Androgenetic Alopecia

Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia

Start date: May 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

A double-blind, randomized, controlled trial of 40 male patients with androgenetic alopecia was conducted. All subject were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical

NCT ID: NCT05970809 Recruiting - Clinical trials for Androgenetic Alopecia

Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss

CS-SAGA-001
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss. Two different device configurations are being explored as part of this study. Device A has novel microneedles, lasers, and additional metal microneedles, while Device B only has novel microneedles and lasers. Participants will receive 12 treatments with either Device A or Device B over the course of 24 weeks. Treatments will be performed on-site every two weeks.

NCT ID: NCT05677438 Recruiting - Clinical trials for Androgenetic Alopecia

A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Start date: December 20, 2022
Phase: Phase 2
Study type: Interventional

This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia

NCT ID: NCT05460611 Recruiting - Clinical trials for Androgenetic Alopecia

1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

Start date: December 7, 2023
Phase: N/A
Study type: Interventional

Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.

NCT ID: NCT05365360 Recruiting - Clinical trials for Androgenetic Alopecia

Sham LaserCap vs. LaserCap SD vs. LaserCap HD+

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1. In addition to medical therapies, FDA-cleared medical devices are now utilized for the treatment of AGA as of 20072. These devices, termed low level laser therapy (LLLT), come in multiple forms including combs, helmets and sports cap wearable devices2. These home-use, wearable devices utilize the ~650 nm wavelength laser light to stimulate the hair follicle mitochondria and thereby promote hair growth, a process termed "photobiomodulation"3. Recent meta-analyses investigating photobiomodulation and LLLT for AGA have noted an increase in fluence or energy delivered per cm is associated with increased hair density3. However, randomized control trials (RCT) with direct comparison of LLLT devices of different fluences has yet to be performed. Accordingly, in the present study we aim to investigate if increasing fluence in LLLT devices is associated with increased hair density by comparing sham LaserCap to LaserCap SD (1.15 J/cm2, low fluence) and LaserCap HD+ (3.93 J/cm2, high fluence) in RCT.